Genfit S.A. (EPA:GNFT)

Market Cap	721.35M +288.6%
Revenue (ttm)	70.85M +0.2%
Net Income	-85.97M
EPS	-1.72
Shares Out	50.02M
PE Ratio	n/a
Forward PE	43.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	206,111
Open	14.12
Previous Close	14.10
Day's Range	13.90 - 14.46
52-Week Range	3.05 - 15.48
Beta	1.14
Analysts	Strong Buy
Price Target	15.90 (+10.26%)
Earnings Date	Sep 29, 2026

About Genfit

Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, which is in Phase 1b clinical trial for the treatment of cholangiocarcin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 161
• Stock Exchange: Euronext Paris
• Ticker Symbol: GNFT

Analyst Summary

According to 4 analysts, the average rating for GNFT stock is "Strong Buy." The 12-month stock price target is €15.90, which is an increase of 10.26% from the latest price.

Price Target

€15.90

(10.26% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error